CHICAGO--(BUSINESS WIRE)--Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg ...
Several coronavirus disease 2019 (COVID-19) vaccines require multiple doses for long-lasting immunity. However, a new study published in the journal Biomacromolecules has developed a promising ...
LONDON, March 30, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces positive ...
5d
Biogen Advances New SKYCLARYS Formulation in Early Trial, Supporting Long-Term Rare Disease Strategy
Biogen Inc. announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing tools for smarter, sharper dec ...
CHICAGO--(BUSINESS WIRE)-- Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback